Ketone supplementation acutely lowers androgen and glucose levels in women with polycystic ovary syndrome: a randomized clinical trial
Authors' conclusion
Ketone supplementation acutely lowers androgen and glucose levels in women with PCOS. These findings highlight the potential for ketone-based therapies as a novel treatment for PCOS and suggest the need for long-term clinical trials to further explore these effects.
Study context
- Population
- Women diagnosed with polycystic ovary syndrome (PCOS)crossover
- Participants
- 20 women
- Comparison
- Ketone supplement vs taste-matched placebo
- Primary endpoint
- Circulating androgen and glucose levels
- Follow-up
- Fasting, after 10 h intervention
Methodological detailsplacebo-controlled, crossover
- Placebo-controlled
- Crossover
Primary result
As reported in the abstract
Androgens
Each group vs placeboEstimate (95% CI)P value
BHB
mean reduction, testosterone −13%(−27 to 1)
P = 0.067BHB
mean reduction, free testosterone −21%(−43% to 1%)
P = 0.057BHB
mean reduction, androstenedione −14%(−29 to 0)
P = 0.050BHB
mean reduction, 11-ketotestosterone −21%(−38 to −4)
P = 0.020Further findings
FPG
mean −10% (−5% to −15%) · P < 0.001
Blood D-β-hydroxybutyrate
P < 0.001
Original publication
Ketone supplementation acutely lowers androgen and glucose levels in women with polycystic ovary syndrome: a randomized clinical trial. Eur J Endocrinol. Published 20 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →